A visual representation of the C-TRACT trial, which evaluated endovascular therapy for patients with post-thrombotic syndrome.
Post-thrombotic syndrome, common after deep-vein thrombosis, can cause severe limb symptoms and impair activity. Studies suggest that endovascular therapy may reduce clinical severity. Research findings from the phase 3 C-TRACT trial are summarized in a new Quick Take video. nej.md/4dGnPJM
Physical examination is shown of the right lower leg and right forearm. He had no known history of chronic liver disease or an immunocompromising condition. What is the most likely diagnosis? nej.md/IC04162026 2/2
A 74-year-old man presented to the emergency department with a 3-day history of a painful laceration on his right leg that he had sustained while jumping into waters off the Gulf Coast of Florida. Two days after the injury to his leg, skin changes had appeared on his right arm. 1/2
Case Records of the Massachusetts General Hospital A 24-Year-Old Man with Depression, Anhedonia, and Fatigue Polysomnogram and multiple sleep latency test.
Case Record of the Massachusetts General Hospital: A 24-year-old man was evaluated in the outpatient psychiatry clinic for anhedonia, somnolence, and extreme fatigue in the context of depression and ongoing substance use. A diagnosis was made. Read the full case details: nej.md/48LEZlL
📖 Further reading:
Original Article by G.M. Marcus et al.: Acute Effects of Coffee Consumption on Health among Ambulatory Adults (CRAVE trial) nej.md/3FCvW8j
An illustration summarizing the results of the CRAVE trial
New Episode: Beyond Journal Club unpacks the CRAVE trial. Is coffee helping or harming our patients' hearts? How should we interpret nutrition research, especially when it feels inconsistent or hard to trust? From @coreimpodcast.bsky.social and NEJM Group. Listen now: nej.md/4sFJc1A
Induction medication for emergency intubation — does the choice matter? NEJM Editorial Fellow Katerina Lin, MD, explains a randomized trial to determine the effects of ketamine vs. etomidate for induction of anesthesia during emergency tracheal intubation. Full RSI trial results: nej.md/44EOlxB
A visual representation of a randomized trial of adjunctive prednisolone for Kawasaki disease.
Coronary-artery lesions develop in 10 to 20% of patients who receive standard treatment for Kawasaki disease. Whether adjunctive glucocorticoids reduce lesion formation is unclear. Research findings for a phase 3 trial are summarized in a new Quick Take video. nej.md/4tMcEnI
Panels A and B: Plain radiographs of the ankle showing an ill-defined, radiolucent lesion on the distal tibia that crossed the physeal scar. Panels C and D: MRI images showing a lesion measuring 14 mm by 16 mm by 12 mm on the distal tibia.
A 16-year-old girl presented with 1 month of ankle pain and 11 days of fever. Radiographs showed an ill-defined, radiolucent distal tibial lesion; on MRI, the lesion was hypointense and surrounded by a hyperintense sclerotic rim. Read the full case details: nej.md/4cnZo1r
#Radiology
Selective Decontamination of the Digestive Tract (SuDDICU trial) nej.md/4nhyeN8
Ianalumab plus Eltrombopag in Immune Thrombocytopenia (phase 3 VAYHIT2 trial) nej.md/49OeoGf
Subscribe to NEJM for the latest medical research: nej.md/subscribe
Images and descriptions of what's new on NEJM.org this week
New in the April 16, 2026, issue of NEJM:
Asundexian for Secondary Stroke Prevention (phase 3 OCEANIC-STROKE trial) nej.md/3O1O0Aj
Adjunctive Prednisolone for Kawasaki Disease (phase 3 trial) nej.md/4dLkjOn
Review Article Sex Hormone Influences on Venous Thrombotic and Cardiovascular Risk Figure 1. Interaction between Hormones and the Coagulation, Fibrinolytic, and Vascular Systems.
Combined oral contraceptives and hormone-replacement therapy increase the risk of venous thromboembolism, although the absolute risk is low. Transdermal estradiol and micronized progesterone carry lower risk. Learn more: nej.md/3Os4aTs
Editorial: Glucocorticoids in Kawasaki Disease — Refining Indications and the Science nej.md/3OwVBHb
A forest plot for the secondary and exploratory outcomes.
In a phase 3, randomized trial involving 3208 children with Kawasaki disease, adding prednisolone to standard primary therapy did not reduce the incidence of coronary-artery lesions at 1 month. Full trial results: nej.md/4dLkjOn
Editorial: Asundexian for Noncardioembolic Ischemic Stroke nej.md/4sOElLP
Original Article | APR 16, 2026 Asundexian for Secondary Stroke Prevention (OCEANIC-STROKE) Figure 1A. Cumulative Incidence of Ischemic Stroke.
In the phase 3 OCEANIC-STROKE trial involving patients with noncardioembolic ischemic stroke or high-risk TIA, asundexian added to antiplatelet therapy led to a lower risk of ischemic stroke without increasing major bleeding. Full trial results: nej.md/3O1O0Aj
Original Article | APR 15, 2026 First-Line Zongertinib in Advanced HER2-Mutant Non–Small-Cell Lung Cancer (Beamion LUNG-1) Figure 1B. Response Assessments and Duration of Progression-free Survival among Patients in Cohort 2
In a phase 1 trial of first-line zongertinib for HER2-mutated non–small-cell lung cancer, an objective response occurred in 76% of patients, with a median progression-free survival of 14.4 months. Full Beamion LUNG-1 trial results: nej.md/4cn0Ssz
Editorial: EGFR’s Poor Sibling nej.md/4cmqRjZ
Key clinical points from the Clinical Practice article "Celiac Disease"
Celiac disease is a chronic, small-intestinal, immune-mediated enteropathy precipitated by exposure to dietary gluten in genetically predisposed persons. It is increasingly common, affecting persons of all ages, and has a wide geographic distribution. Learn more: nej.md/3QrsmWF
The New England Journal of Medicine Immunogenicity and Safety of vYF, a Yellow Fever Vaccine A Research Summary based on Feroldi E et al. | 10.1056/NEJMoa2505665 | Published on April 9, 2026 Visual representations of the patients in the trial and the treatments they were assigned. Read the full Research Summary at NEJM.org.
In a phase 2 trial, a new yellow fever vaccine grown in Vero cells was shown to elicit immunogenicity similar to that of the standard yellow fever vaccine. Full trial results and Research Summary: nej.md/4sq5Lay
#InfectiousDisease
AI Grand Rounds Episode 41 Doctronic’s Autonomous AI with Dr. Byron Crowe Photo of Dr. Crowe
In the latest episode of AI Grand Rounds, Dr. Byron Crowe, chief medical officer of Doctronic, describes how administrative complexity can interfere with timely, effective treatment, and how #AI may help address those challenges. Listen to the full episode: nejm.ai/ep41
Original Article Wrist Splinting versus a Placebo Soft Bandage for Carpal Tunnel Syndrome I. Atroshi, J. Nordenskjöld, and K. Möllestam An illustration of a wrist splint (left) and soft bandage (right) on a purple background
Among pts w/ carpal tunnel syndrome randomized to a rigid wrist splint vs. placebo bandage, 12-week change in symptom scores was not significantly different and proportion undergoing surgery w/in 1 year was similar between the 2 groups. Full trial results in NEJM Evidence: eviden.cc/4rFztrz
Our latest video in our partnership with @glaucomflecken.bsky.social summarizes a trial evaluating the clinical efficacy of tecovirimat against human clade II mpox. Read the full study for free: nej.md/DrG38
A visual representation of a a phase 2 trial on the immunogenicity and safety of vYF, a yellow fever vaccine.
To help ensure a sufficient supply of yellow fever vaccine, a next-generation, live-attenuated vaccine — vYF — has been developed. Research findings on its safety and immunogenicity are summarized in a new Quick Take video. nej.md/41YGGZe
#InfectiousDisease
The New England Journal of Medicine Mezagitamab in Primary Immune Thrombocytopenia A Research Summary based on Kuter DJ et al. | 10.1056/NEJMoa2513120 | Published on April 9, 2026 Visual representations of the patients in the trial and the treatments they were assigned. Read the full Research Summary at NEJM.org.
Among adults with persistent or chronic ITP, the incidence of adverse events with mezagitamab appeared to be similar to that with placebo. Mezagitamab treatment appeared to result in increased platelet counts at all three doses tested. Full trial results and Research Summary: nej.md/41Tmg3Q
In a new blog post, Michelle Kittleson, MD, PhD, explains how a patient’s reference to a late-70s country hit inspires a framework for shared decision-making. Read “Kenny Rogers and the Art of Shared Decision-Making”: voices.nejm.org/doi/full/10....
Figures showing prevalence of type 2 diabetes among U.S. youths younger than 20 years of age.
Findings from an analysis of deidentified electronic health record data from a national database indicate that the prevalence of youth-onset type 2 diabetes has increased substantially during the past decade. Full study results: nej.md/3OddlHt
#Pediatrics #Endocrinology #T2D
A new article summarizes the epidemiology, diagnosis, and management of celiac disease and highlights serologic testing, biopsy confirmation, associated autoimmune conditions, and a gluten-free diet as treatment. Read the full article: nej.md/3QrsmWF
#Gastroenterology #Immunology
The New England Journal of Medicine Strategies for Hypertension Control in Low-Income Patients A Research Summary based on Mills KT et al. | 10.1056/NEJMoa2504068 | Published on April 9, 2026 Visual representations of the patients in the trial and the treatments they were assigned. Read the full Research Summary at NEJM.org.
Among low-income patients with hypertension, a multifaceted, team-based strategy resulted in a greater reduction in systolic blood pressure than enhanced usual care. Full IMPACTS-BP trial results and Research Summary: nej.md/4cuvnhA
#Cardiology
Editorial: Stenting for Post-Thrombotic Syndrome — A Step Forward nej.md/4mhaFoJ
Society of Interventional Radiology Annual Meeting Original Article | APR 13, 2026 | NEJM.org Endovascular Therapy for Post-Thrombotic Syndrome — A Randomized Trial (C-TRACT) Figure 2A. Severity of Post-Thrombotic Syndrome According to Venous Clinical Severity Score (VCSS).
Among patients w/ moderate or severe PTS, the addition of endovascular therapy to standard care resulted in less severe PTS and better quality of life at 6 months than standard care alone but w/ a higher risk of bleeding. Full phase 3 C-TRACT trial results: nej.md/3QsqxJ2
#SIR26TOR | @sirweb.org
